Adaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
Open